Drug Profile
Eculizumab biosimilar - Generium
Alternative Names: ElizariaLatest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator GENERIUM Pharmaceuticals
- Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antihypertensives; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
- 20 Apr 2020 GENERIUM completes phase III NAP trial in Paroxysmal nocturnal haemoglobinuria in Russia (Parenteral) (NCT04679103)
- 07 Dec 2019 Efficacy, safety, pharmacokinetics and immunogenicity data from a phase III trial in Paroxysmal nocturnal haemoglobinuria presented at 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2019)